✦ LIBER ✦

Review of clinical and haematological response to low-dose cytosine arabinoside in acute myeloid leukaemia

✍ Scribed by Mordechai Shtalrid; Joseph Lotem; Leo Sachs; Alain Berrebi

Book ID: 114790791
Publisher: John Wiley and Sons
Year: 2009
Tongue: English
Weight: 635 KB
Volume: 38
Category: Article
ISSN: 0902-4441
DOI: 10.1111/j.1600-0609.1987.tb01416.x

No coin nor oath required. For personal study only.

📜 SIMILAR VOLUMES

Low dose cytosine arabinoside in the tre

Low dose cytosine arabinoside in the treatment of myeloid leukaemias and myelodysplastic syndromes

✍ M. Murray; P. Sarsfield; E. Lawlor; S. R. McCann 📂 Article 📅 1988 🏛 Springer-Verlag 🌐 English ⚖ 337 KB

Low dose cytosine arabinoside: partial r

Low dose cytosine arabinoside: partial remission of acute myeloid leukaemia without evidence of differentiation induction

✍ Michael Leyden; Arumigum Manoharan; Andrew Boyd; Zhao Ming Cheng; John Sullivan 📂 Article 📅 1984 🏛 John Wiley and Sons 🌐 English ⚖ 389 KB

High-dose cytosine arabinoside: Clinical

High-dose cytosine arabinoside: Clinical response to therapy in acute leukemia

✍ Early, A. P. ;Preisler, H. D. ;Higby, D. J. ;Brecher, M. ;Browman, G. ;McBride, 📂 Article 📅 1982 🏛 John Wiley and Sons 🌐 English ⚖ 664 KB

High dose cytosine arabinoside (HD-AraC) was evaluated 1) as remission induction therapy for refractory acute leukemia and high risk AML, 2) as augmentation therapy for acute leukemia, and 3) as conditioning therapy prior to allogeneic bone marrow transplantation for acute leukemia. Seven of 10 pati

High-dose cytosine arabinoside: response

High-dose cytosine arabinoside: response to therapy in acute leukaemia and non-Hodgkin's lymphoma

✍ Ama Rohatiner; M. L. Slevin; H. S. Dhaliwal; J. S. Malpas; T. A. Lister 📂 Article 📅 1984 🏛 Springer 🌐 English ⚖ 349 KB

The metabolism of cytosine arabinoside a

The metabolism of cytosine arabinoside as a predictive test for clinical response to the drug in acute myeloid leukaemia

✍ J.F. Smyth; A.B. Robins; C.L. Leese 📂 Article 📅 1976 🏛 Elsevier Science ⚖ 590 KB

Clofarabine and high-dose cytosine arabi

Clofarabine and high-dose cytosine arabinoside in the treatment of refractory or relapsed acute myeloid leukaemia

✍ Eric Tse; Anskar Y. H. Leung; Joycelyn Sim; Harold K. K. Lee; Herman S. Y. Liu; 📂 Article 📅 2011 🏛 Springer 🌐 English ⚖ 98 KB

Clofarabine (40 mg/m^2^/day × 5) and high-dose cytosine arabinoside (Ara-C, 1–2 g/m^2^/day × 5) were used in 10 men and 11 women, at a median age of 45 (22–62) years, with refractory (__N__ = 4) and relapsed (__N__ = 17) acute myeloid leukaemia, after a median of 3 (2–5) prior regimens. Grade 4 myel